Navigation Links
SleepQuest Compliance Again Doubles Industry Average
Date:2/3/2009

Study Shows Patients Consistently Adhere to Sleep Apnea Treatment

SAN CARLOS, Calif., Feb. 3 /PRNewswire/ -- SleepQuest announced today that an internal study has shown their patients comply with Obstructive Sleep Apnea treatment at a rate nearly twice the industry average.

Analysis performed in October 2008 looked at Northern California patients who received home sleep testing and treatment with Positive Airway Pressure beginning in early 2008. Of the patients surveyed, 91% were compliant, while known industry standards are closer to 50%. This percentage is based on the average number of treatment hours for patients using CPAP more than four hours per night.

"Compliance is dependent upon the caregiver's expertise with the many different complications that might occur with PAP treatment," said Robert Koenigsberg, SleepQuest President/CEO. "Our resolute focus is to troubleshoot problems that patients may experience and to find the right solutions for them."

Obstructive Sleep Apnea (OSA) is a dangerous condition in which soft tissues in the throat collapse during sleep, triggering a partial awakening to prevent suffocation. During PAP treatment (Continuous, Bi-level and AutoPAP), the patient receives positive air flow via a mask or nasal interface that keeps the airway open, allowing regular, quiet breathing and restful sleep to occur. Patients frequently have a hard time adjusting to treatment. Trial and error is often required to find the right combination of facial interface type, the most appropriate PAP device, and air flow settings that are most comfortable. If patients find it unpleasant, difficult to operate, or ineffective, they may lose interest in adhering to treatment.

"Most providers of CPAP therapy are general home care companies," said Lori Schulman, SleepQuest's Director of Contracting. "They focus on providing 1500 different products aimed at 150 different disease states, rather than providing comprehensive follow-up for OSA patients."

SleepQuest, in contrast, is a disease management specialist that has been a leader in home sleep testing and treatment of Sleep Apnea for more than 14 years. A similar analysis of patient compliance from 1999 also showed a treatment adherence rate of over 90%.

"Our Sleep Care Specialists work directly with patients and their doctors to find the solution that works best and is easiest to sustain," said Koenigsberg. "We help our patients feel better as they continue their treatment. That's why our rates are so high."


'/>"/>
SOURCE SleepQuest
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SleepQuest Achieves Coveted Accreditation
2. SleepQuest Tireless in Pursuit of Good Sleep
3. Latest Sleep Disorder Technology Tested With SleepQuest
4. SleepQuest to Open San Francisco Office
5. SleepQuest Raises Awareness of Sleep Disorders
6. SleepQuest Launches Updated Web Site
7. Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
11. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):